FIELD: medicine.
SUBSTANCE: group of inventions refers to therapy and cardiology, and is intended for use in the treatment of cardiovascular diseases. To reduce triglyceride and apolipoprotein B levels in a patient with an initial fasting triglyceride level of 500 to 2,000 mg/dl, the patient is administered a pharmaceutical composition containing at least 96% by weight of ethyl ester of eicosapentaenoic acid 4 g per day for a period effective to reduce the level fasting triglycerides by at least 15% from baseline fasting triglycerides and to reduce apolipoprotein B by at least 5% from baseline apolipoprotein B prior to initial administration of the pharmaceutical composition. In another embodiment, a method is provided for lowering triglycerides and apolipoprotein B in a patient with a baseline fasting triglyceride level of 500 to 2,000 mg/dL and naive for statin therapy.
EFFECT: use of the group of inventions makes it possible to increase the efficiency and safety of the said composition.
21 cl, 1 ex
